Welcome to our dedicated page for Anixa Biosciences SEC filings (Ticker: ANIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to track how Anixa Biosciences funds its CER-T ovarian cancer trial or when breast-cancer vaccine data hits the wire? This page brings every Anixa Biosciences SEC filing into one view, updated the moment it posts to EDGAR.
Search engines often send biotech investors here because we answer real questions—like “Where do I find the Anixa Biosciences quarterly earnings report 10-Q filing?” or “Which executives bought shares in the latest Anixa Biosciences insider trading Form 4 transactions?”—with direct links and plain-English context.
How our AI helps:
- Instant, jargon-free digests that make understanding Anixa Biosciences SEC documents with AI simple.
- Real-time alerts for Anixa Biosciences Form 4 insider transactions so you never miss management’s moves.
- Side-by-side trend charts that turn dense R&D spending notes from the 10-K into actionable visuals.
Want the quick version of a 250-page annual report? Our platform offers an Anixa Biosciences annual report 10-K simplified summary that pinpoints cash runway, partnership revenue, and key risk factors. Need fresh numbers between quarters? The AI-layered Anixa Biosciences earnings report filing analysis highlights trial-expense swings inside each 10-Q.
Material event on pipeline data? Dive straight into the Anixa Biosciences 8-K material events explained brief. Curious about pay packages that drive retention? The Anixa Biosciences proxy statement executive compensation section details option grants without legalese.
No more CTRL-F guessing. From Anixa Biosciences executive stock transactions Form 4 to every funding disclosure, Stock Titan’s AI ensures you spend minutes, not hours, finding what matters.
Anixa Biosciences, Inc. (ANIX) filed a shelf registration on Form S-3 that outlines the types of securities it may offer, exhibits that will be incorporated, and selected financial and offering metrics. The prospectus lists potential securities including common stock, preferred stock, purchase contracts, warrants, subscription rights, depositary shares and units. It incorporates multiple recent SEC reports including the annual report for the year ended
Anixa Biosciences (ANIX) reported continued operating losses but states it has sufficient liquidity for over 12 months. The company recorded net losses of $2.3 million for the three months and $8.3 million for the nine months ended July 31, 2025, with losses from operations of $2.4 million and $8.8 million, respectively. Cash, cash equivalents and short-term investments totaled $16,029,000 at July 31, 2025, down from approximately $19,924,000 at October 31, 2024, a reduction of about $3.9 million for the nine months. During the period the company raised approximately $1.924 million, net, from an at-the-market equity offering of 611,686 shares and issued options under its 2018 Share Incentive Plan (1,430,000 granted during the nine months). Stock-based compensation was $829,000 and $2,822,000 for the three- and nine-month periods, respectively. The company continues a 2,000 sq. ft. operating lease for its San Jose office with base rent of approximately $5,000 per month.
Form 4 filing for Anixa Biosciences (ANIX): Company director Lewis H. Titterton, Jr. bought 10,000 common shares on 07/31/2025 at $3.08 per share, an outlay of roughly $30.8 k.
The purchase lifts his direct holding to 953,334 shares. No sales or derivative transactions were disclosed. Because directors are presumed to possess intimate knowledge of corporate prospects, open-market buying is generally interpreted as a positive signal of confidence rather than a routine option exercise.
Form 4 filing overview: On 07/11/2025, Anixa Biosciences (ANIX) Chief Executive Officer Amit Kumar executed an open-market purchase (Code “P”) of 5,000 common shares at $3.15 per share, an aggregate value of roughly $15,750.
Following the transaction, Kumar’s direct ownership increased to 574,925 shares. No derivative securities were reported and the filing was submitted as a single-person report on 07/14/2025.
The purchase represents a ~0.9% increment to Kumar’s previously held position and signals a modest vote of confidence from the company’s most senior executive. However, given the limited dollar amount relative to both his existing stake and the company’s overall share count, the transaction is unlikely to be viewed as a materially game-changing event by the market.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
